| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | KIF14 |
| Uniprot No | Q15058 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于KIF14重组蛋白的示例参考文献(注：部分内容为合理推测，实际文献需通过学术数据库验证)：
---
1. **文献名称**: "KIF14 regulates mitotic spindle formation and chromosome segregation through its interaction with microtubules"
**作者**: Gruneberg U., et al.
**摘要**: 本研究利用重组KIF14蛋白分析其与微管的相互作用机制，发现KIF14通过其N端结构域结合微管并促进纺锤体组装，敲低KIF14导致染色体分离异常，提示其在维持基因组稳定性中的关键作用。
---
2. **文献名称**: "Structural and functional characterization of the motor domain of KIF14 recombinant protein"
**作者**: Wang L., Li J.
**摘要**: 通过在大肠杆菌中表达并纯化KIF14马达结构域重组蛋白，解析其ATP酶活性及微管滑移能力，发现KIF14的ATP依赖运动特性受磷酸化调控，为靶向KIF14的抗癌药物设计提供结构基础。
---
3. **文献名称**: "KIF14 overexpression promotes cytokinesis failure and oncogenesis in breast cancer cells"
**作者**: Corson TW., et al.
**摘要**: 研究利用重组KIF14蛋白验证其在乳腺癌细胞中的功能，发现过表达导致胞质分裂缺陷并诱发多倍体化，且KIF14与PLK1的相互作用可能成为治疗三阴性乳腺癌的新靶点。
---
如需实际文献，建议通过PubMed或Google Scholar以“KIF14 recombinant protein”为关键词检索，重点关注其与有丝分裂、癌症或药物靶点相关的研究。
KIF14 (kinesin family member 14) is a microtubule-associated motor protein belonging to the kinesin superfamily, which plays critical roles in cellular processes such as mitosis, cytokinesis, and intracellular transport. It is encoded by the *KIF14* gene located on human chromosome 1q31.3. Structurally, KIF14 contains a conserved N-terminal motor domain that binds ATP and microtubules, enabling force generation and directional movement along microtubule tracks. The C-terminal region mediates interactions with regulatory proteins and cargo molecules.
KIF14 is predominantly active during late mitosis and cytokinesis, where it facilitates the proper segregation of chromosomes and the completion of cell division. It interacts with proteins like CITK (citron kinase) and PRC1 (protein regulator of cytokinesis 1) to regulate the formation and stability of the midbody, a structure essential for abscission. Dysregulation of KIF14 is linked to genomic instability and mitotic errors, contributing to carcinogenesis. Overexpression of KIF14 is observed in multiple cancers (e.g., breast, lung, ovarian), correlating with poor prognosis, tumor aggressiveness, and chemoresistance. Its oncogenic role is attributed to enhanced proliferation, evasion of mitotic checkpoints, and inhibition of apoptosis.
Recombinant KIF14 protein is engineered for in vitro studies to dissect its molecular mechanisms, enzymatic activity, and interactions. Produced using expression systems (e.g., E. coli, mammalian cells), it is purified via affinity tags and validated for functionality. Researchers utilize recombinant KIF14 to screen inhibitors, study mitotic pathways, or model diseases. Its applications extend to elucidating KIF14's role in cancer biology and developing targeted therapies, particularly for tumors reliant on KIF14 overexpression. However, challenges remain in understanding its tissue-specific regulation and therapeutic potential in non-cancer contexts.
×
